Sipavax LLC is a pioneering company based in Albuquerque, NM, that specializes in providing innovative solutions for cerebrovascular disease. Their groundbreaking technology, Lamiflo, offers a non-pharmacologic approach to treating this condition, revolutionizing the current stroke protocol. Lamiflo can be administered in the pre-hospital phase, expanding the number of patients eligible for treatment and even benefiting those who do not qualify for traditional therapies. With a focus on acute large vessel occlusion stroke, Sipavax LLC aims to conduct clinical trials and obtain FDA approval for Lamiflo, ultimately improving the safety and efficacy of stroke treatment.
Driven by a global emergency, Sipavax LLC recognizes the urgent need for effective interventions in cerebrovascular disease. Their disruptive technology has the potential to transform the landscape of stroke care, offering hope to patients at risk of a second stroke even days to months after their initial event. With a comprehensive plan that includes securing grants, conducting clinical trials, and obtaining commercialization, Sipavax LLC is committed to advancing the field of stroke treatment and making a lasting impact on the lives of patients worldwide.
Generated from the website